Ophthalmic research · 2005
Expression of tumor necrosis factor alpha and matrix metalloproteinase-9 in surgically induced necrotizing scleritis.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dennis Consuela, Wright Eugene, Kohn Stephanie, Gavin Iii James R, Parkin Christopher G, Edelman Steven V
Аннотация
OBJECTIVES: To identify clinicians' current practice behaviors, attitudes, and obstacles shaping continuous glucose monitoring (CGM) use.
STUDY DESIGN: This structured survey asked clinicians about their practice environments, their views on the value of CGM and the importance of comprehensive training and education, their preferred prescribing channels for CGM, and details specific to each practice type.
METHODS: Survey participants were selected by PureSpectrum, which used the PureScore system to evaluate participant suitability, collect data, and analyze results. The data show the percentage of respondents in each clinician group who answered each question.
RESULTS: Responses from 101 primary care physicians (PCPs) and 106 endocrinologists were obtained for analysis. Levels of familiarity with the newest CGM technologies were consistent among PCPs and endocrinologists. A large percentage of both PCPs and endocrinologists indicated that concerns about patients' ability to afford CGM were a main reason for prescribing traditional blood glucose monitoring. The majority of PCPs (69%) and endocrinologists (73%) who prescribe CGM prefer the durable medical equipment (DME) channel. Most PCPs (92%) and endocrinologists (91%) indicated they would likely prescribe CGM through the DME channel more often if those suppliers offered disease education and coaching. A large percentage of endocrinologists (76%) and a smaller percentage of PCPs (45%) reported feeling pressured by health insurers to prescribe through the pharmacy channel.
CONCLUSION: Clinician prescribing behaviors continue to be shaped by systemic barriers, including insurance pressures and concerns about patient ability/readiness to use CGM technology.
STUDY DESIGN: This structured survey asked clinicians about their practice environments, their views on the value of CGM and the importance of comprehensive training and education, their preferred prescribing channels for CGM, and details specific to each practice type.
METHODS: Survey participants were selected by PureSpectrum, which used the PureScore system to evaluate participant suitability, collect data, and analyze results. The data show the percentage of respondents in each clinician group who answered each question.
RESULTS: Responses from 101 primary care physicians (PCPs) and 106 endocrinologists were obtained for analysis. Levels of familiarity with the newest CGM technologies were consistent among PCPs and endocrinologists. A large percentage of both PCPs and endocrinologists indicated that concerns about patients' ability to afford CGM were a main reason for prescribing traditional blood glucose monitoring. The majority of PCPs (69%) and endocrinologists (73%) who prescribe CGM prefer the durable medical equipment (DME) channel. Most PCPs (92%) and endocrinologists (91%) indicated they would likely prescribe CGM through the DME channel more often if those suppliers offered disease education and coaching. A large percentage of endocrinologists (76%) and a smaller percentage of PCPs (45%) reported feeling pressured by health insurers to prescribe through the pharmacy channel.
CONCLUSION: Clinician prescribing behaviors continue to be shaped by systemic barriers, including insurance pressures and concerns about patient ability/readiness to use CGM technology.